| 80.5 8 (11.03%) | 12-05 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 95.77 |
1-year : | 111.86 |
| Resists | First : | 82 |
Second : | 95.77 |
| Pivot price | 65.18 |
|||
| Supports | First : | 62.22 |
Second : | 50 |
| MAs | MA(5) : | 73.52 |
MA(20) : | 63.67 |
| MA(100) : | 50.59 |
MA(250) : | 0 | |
| MACD | MACD : | 4.6 |
Signal : | 2.8 |
| %K %D | K(14,3) : | 88.8 |
D(3) : | 85.3 |
| RSI | RSI(14): 79.3 |
|||
| 52-week | High : | 82 | Low : | 23.17 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ DRUG ] has closed above the upper band by 3.2%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 97% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 82.09 - 82.42 | 82.42 - 82.7 |
| Low: | 71.34 - 71.71 | 71.71 - 72.02 |
| Close: | 79.81 - 80.46 | 80.46 - 81.02 |
Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.
Sat, 06 Dec 2025
Bright Minds Biosciences (NASDAQ:DRUG) Reaches New 1-Year High - Here's Why - MarketBeat
Thu, 04 Dec 2025
Bright Minds Biosciences (NASDAQ:DRUG) Sees Unusually-High Trading Volume - Should You Buy? - MarketBeat
Thu, 04 Dec 2025
An Intrinsic Calculation For Bright Minds Biosciences Inc. (CSE:DRUG) Suggests It's 44% Undervalued - simplywall.st
Thu, 04 Dec 2025
Bright Minds Biosciences (NASDAQ:DRUG) Targets Neurological Disorders - Kalkine Media
Wed, 03 Dec 2025
Bright Minds Biosciences (NASDAQ:DRUG) Shares Up 7.2% - Still a Buy? - MarketBeat
Mon, 01 Dec 2025
Cantor Fitzgerald reiterates Overweight rating on Bright Minds Biosciences stock By Investing.com - Investing.com South Africa
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 7 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 20.3 (%) |
| Held by Institutions | 77.5 (%) |
| Shares Short | 273 (K) |
| Shares Short P.Month | 231 (K) |
| EPS | -0.99 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.32 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -18.4 % |
| Return on Equity (ttm) | -30.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -8 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -82.15 |
| PEG Ratio | 0 |
| Price to Book value | 10.99 |
| Price to Sales | 0 |
| Price to Cash Flow | -72.34 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|